Sinopec deploys 65,000 Sercel land nodes for complex 3D survey in Mexico Paris, France – August 26, 2025 Viridien has announced that its Sensing & Monitoring business line, marketed under the Sercel brand, has sold and successfully delivered a complete land nodal acquisition system to Sinopec, one of the world’s leading energy companies. The system, featuring 65,000 WiNG nodes, is currently being deployed to acquire a 3D seismic survey spanning approximately 3,000 square kilometers in the Tabasco and Veracr ...

Sinopec deploys 65,000 Sercel land nodes for complex 3D survey in Mexico Paris, France – August 26, 2025 Viridien has announced that its Sensing & Monitoring business line, marketed under the Sercel brand, has sold and successfully delivered a complete land nodal acquisition system to Sinopec, one of the world’s leading energy companies. The system, featuring 65,000 WiNG nodes, is currently being deployed to acquire a 3D seismic survey spanning approximately 3,000 square kilometers in the Tabasco and Veracr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39811 Dogwood Therapeutics, Inc. (866) 620-8655 (Registrant's telephone number) Not applicable (Former name, f ...

Exhibit 99.1 Dogwood Therapeutics Reports Second Quarter 2025 Financial Results - Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain ("CINP") Phase 2b study interim data readout remains on track for Q4 2025 - - Low discontinuation rate (5.8%) due to adverse events in the first 38 patients completing the trial suggests Halneuron® and placebo treatment have been generally well tolerated - - Cash on hand of $13.4 million provides oper ...

Viridien Société Anonyme with a share capital of €7,180,449Registered office: 27 avenue Carnot, 91300 MassyNo.: 969 202 241 – RCS Evry 2025 Interim Financial Report available Paris, France – July 31, 2025 Viridien announced that its interim financial report as at June 30, 2025 was filed today with the Autorité des Marchés Financiers (AMF). This document is available on the Company’s website: https://www.viridiengroup.com/ under the Investors section (both in “Regulated information” and “Results and Publicat ...

Paris, France – July 17, 2025 Q2 2025 financial results and conference call Viridien will announce its second quarter 2025 results on Thursday, July 31, after market close. The press release and presentation will be made available on www.viridiengroup.com at 5.45 pm (CET)An English-language conference call is scheduled at 6.00 pm (CET) on the same day Participants must register for the conference call by clicking here to receive a dial-in number and PIN code. Participants may also join the live webcast by c ...

Core Insights - Viridien has launched the Sercel Accel, the first onshore drop node solution aimed at transforming land seismic data acquisition [1][5] - The Accel solution significantly reduces deployment time and labor requirements, enhancing operational efficiency and reducing costs by up to 30% [2][5] Product Features - Accel eliminates the need for nodes to be buried or planted, streamlining logistics and improving in-field agility [2] - The solution is powered by the Sercel QuietSeis MEMS sensor, ensuring total data integrity and reliability [3] - Accel includes modular Solution Packs that combine nodes, software, and services, allowing customization based on project needs [4] Company Overview - Viridien is a technology and Earth data company focused on sustainable solutions for natural resources and infrastructure challenges, employing around 3,400 people globally [6]

Part I: Financial Information [Item 1. Consolidated Financial Statements](index=3&type=section&id=Item%201.%20Consolidated%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for Q1 2025, detailing a **$10.9 million net loss**, **$97.0 million total assets**, and financing activities that improved equity and Nasdaq compliance, despite going concern doubts [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (Unaudited) | Account | March 31, 2025 ($) | December 31, 2024 ($) | | :--- | :--- | :--- | | Cash | $17,539,004 | $14,847,949 | | Total Assets | $96,984,688 | $94,308,246 | | Total Liabilities | $14,235,733 | $30,027,223 | | Total Stockholders' Equity (Deficit) | $7,086,931 | $(10,124,339) | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Condensed Consolidated Statements of Operations (Unaudited) | Account | Three Months Ended March 31, 2025 ($) | Three Months Ended March 31, 2024 ($) | | :--- | :--- | :--- | | Revenue | $0 | $0 | | Research and development | $2,436,998 | $343,717 | | General and administrative expenses | $1,992,928 | $970,384 | | Loss from operations | $(4,429,926) | $(1,314,101) | | Loss on debt conversion with related party | $(6,134,120) | $0 | | Net loss | $(10,924,952) | $(1,291,335) | | Net loss per common share, basic and diluted | $(8.45) | $(1.68) | [Condensed Consolidated Statements of Changes in Series A Non-Voting Convertible Preferred Stock and Stockholders' Equity (Deficit)](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity%20%28Deficit%29) - Stockholders' equity (deficit) improved from a deficit of **$(10.1) million** at year-end 2024 to positive equity of **$7.1 million** at March 31, 2025, primarily driven by the conversion of debt into **$25.0 million** of Series A-1 Preferred Stock and **$4.3 million** in net proceeds from a common stock offering, which offset the **$10.9 million** net loss for the quarter[14](index=14&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Condensed Consolidated Statements of Cash Flows (Unaudited) | Cash Flow Activity | Three Months Ended March 31, 2025 ($) | Three Months Ended March 31, 2024 ($) | | :--- | :--- | :--- | | Net cash used in operating activities | $(4,682,554) | $(937,414) | | Net cash provided by financing activities | $7,372,378 | $0 | | Net increase (decrease) in cash | $2,689,824 | $(937,414) | | Cash, end of period | $17,539,004 | $2,379,532 | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) These notes detail accounting policies, the company's pre-revenue biopharmaceutical nature, significant development risks, and substantial doubt about going concern, alongside the Pharmagesic acquisition and Q1 2025 financing activities crucial for Nasdaq compliance - The company is a pre-revenue, development-stage biopharmaceutical company focused on developing medicines for pain and fatigue-related disorders, with a pipeline including Halneuron® for pain and antiviral therapies IMC-1 and IMC-2[19](index=19&type=chunk) - Management has concluded there is substantial doubt about the Company's ability to operate as a going concern for at least 12 months from the financial statement issuance date, as current cash is insufficient to fund operations beyond Q1 2026[24](index=24&type=chunk) - In March 2025, the company converted **$19.5 million** in principal and **$0.4 million** in accrued interest from a related-party loan into 284.2638 shares of Series A-1 Preferred Stock, resulting in a **$6.1 million** loss on debt extinguishment[83](index=83&type=chunk)[86](index=86&type=chunk) - In March 2025, the company raised approximately **$4.25 million** in net proceeds through a registered direct offering of 578,950 shares of common stock at **$8.26 per share**[23](index=23&type=chunk)[110](index=110&type=chunk) - The company regained compliance with Nasdaq's minimum stockholders' equity requirement on April 8, 2025, following the debt conversion and equity offering[25](index=25&type=chunk)[26](index=26&type=chunk)[141](index=141&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial condition and operational results, highlighting its pre-revenue biopharmaceutical status, increased R&D and G&A expenses, and liquidity challenges with **$17.5 million cash** funding operations only through Q1 2026, raising going concern doubts - The company's lead product candidate, Halneuron®, commenced its Phase 2b clinical trial (HALT-CINP-203) in Q1 2025 for chemotherapy-induced neuropathic pain, with an interim analysis expected in Q4 2025 and top-line data anticipated in the second half of 2026[129](index=129&type=chunk) Operating Expense Comparison (Q1 2025 vs. Q1 2024) | Expense Category | Q1 2025 ($) | Q1 2024 ($) | Change ($) | | :--- | :--- | :--- | :--- | | Research and Development | $2.4 million | $0.3 million | +$2.1 million | | General and Administrative | $2.0 million | $1.0 million | +$1.0 million | - The increase in R&D expenses was primarily due to **$1.8 million** in costs for the HALT-CINP-203 study, while the rise in G&A expenses was driven by **$0.6 million** in legal/professional fees related to the Combination and increased personnel costs[143](index=143&type=chunk)[144](index=144&type=chunk) - As of March 31, 2025, the company had **$17.5 million** in cash, which is anticipated to fund operations only through the first quarter of 2026, raising substantial doubt about the company's ability to continue as a going concern[145](index=145&type=chunk)[150](index=150&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As a smaller reporting company, the company is not required to provide disclosures on quantitative and qualitative market risk - This item is not required for smaller reporting companies[162](index=162&type=chunk) [Item 4. Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of the end of the reporting period, the CEO and CFO concluded that the company's disclosure controls and procedures were effective[164](index=164&type=chunk) - There were no changes in internal control over financial reporting during the quarter that materially affected, or are reasonably likely to materially affect, such controls[165](index=165&type=chunk) Part II: Other Information [Item 1. Legal Proceedings](index=32&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no pending or ongoing material legal proceedings - The company does not currently have any pending or ongoing material litigation[167](index=167&type=chunk) [Item 1A. Risk Factors](index=32&type=section&id=Item%201A.%20Risk%20Factors) This section refers readers to the detailed risk factors outlined in the company's 2024 Annual Report on Form 10-K - Readers are referred to the risk factors section of the 2024 Annual Report on Form 10-K for information on risks that could materially affect the business[168](index=168&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities or use of proceeds during the period - None reported[169](index=169&type=chunk) [Item 3. Defaults Upon Senior Securities](index=32&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None reported[170](index=170&type=chunk) [Item 4. Mine Safety Disclosures](index=32&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - Not applicable[171](index=171&type=chunk) [Item 5. Other Information](index=32&type=section&id=Item%205.%20Other%20Information) This section discloses no Rule 10b5-1 trading arrangement changes by directors or officers, and the board's ratification of a Series A Preferred Stock dividend payment on May 8, 2025 - No director or officer adopted or terminated a Rule 10b5-1 trading arrangement during the three months ended March 31, 2025[172](index=172&type=chunk) - On May 8, 2025, the board of directors ratified the payment of a dividend of 55.345 shares of Series A Preferred Stock to holders of Series A Preferred Stock[173](index=173&type=chunk) [Item 6. Exhibits](index=32&type=section&id=Item%206.%20Exhibits) This section refers to the Exhibit Index, listing all documents filed as exhibits with this Quarterly Report on Form 10-Q - Refers to the Exhibit Index for a list of filed documents[174](index=174&type=chunk)

Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2025 Financial Results - Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 - - Cash on hand of $17.5M provides operational runway through Q1 2026 - ATLANTA, Ga., May 8, 2025 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechno ...

Core Insights - Viridien has sold its Sercel Marlin™ Offshore Logistics management solution to Oil and Natural Gas Corporation (ONGC) to improve operational efficiency and safety in ONGC's Western offshore exploration and production (E&P) operations in India [1][2] - The deal includes a five-year contract for dedicated on-premises software and support services, which will enhance ONGC's logistics through real-time vessel tracking and improved operational planning [1][2] - The integration of advanced AI and machine learning algorithms in the Sercel Marlin solution aims to future-proof ONGC's operations and support its carbon neutrality objectives [2][3] Company Overview - Viridien is a technology and digital company focused on Earth data, aiming to resolve complex challenges in natural resources, energy transition, and infrastructure [4] - The company employs approximately 3,400 people globally and is listed on Euronext Paris SA under the ticker VIRI [4]